title: Pharmacological treatments for smoking cessation.
abstract: OBJECTIVE
  Among the 3 first-line smoking cessation treatments (nicotine replacement therapy [NRT], bupropion, and varenicline), which is most effective in helping people who smoke achieve and maintain abstinence from smoking for at least 6 months, and what serious adverse events are associated with each?
  
  
  CONCLUSIONS
  Higher rates of smoking cessation were associated with NRT (17.6%) and bupropion (19.1%) compared with placebo (10.6%). Varenicline (27.6%) and combination NRT (31.5%) (eg, patch plus inhaler) were most effective for achieving smoking cessation. None of the therapies was associated with an increased rate of serious adverse events.
authors.affiliation: Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom2Cochrane Tobacco Addiction Group, University of Oxford, Oxford, United Kingdom.
authors.forename: Kate
authors.initials: K
authors.lastname: Cahill
authors.affiliation: Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
authors.forename: Sarah
authors.initials: S
authors.lastname: Stevens
authors.affiliation: Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom2Cochrane Tobacco Addiction Group, University of Oxford, Oxford, United Kingdom.
authors.forename: Tim
authors.initials: T
authors.lastname: Lancaster
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001552:Benzazepines / Q000627:therapeutic use*; D016642:Bupropion / Q000627:therapeutic use*; D006801:Humans; D018722:Nicotinic Agonists / Q000627:therapeutic use*; D011810:Quinoxalines / Q000627:therapeutic use*; D016540:Smoking Cessation / Q000379:methods*; D061485:Tobacco Use Cessation Devices
chemical_list: D018687:Antidepressive Agents, Second-Generation; D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion